

October 13, 2009

Press Release

[Mitsubishi Tanabe Pharma Corporation](#)

Establishment of Pharmaceutical Sales & Marketing Company and Reorganization of Group Companies in the U.S.

In July 2009, Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka; President & CEO: Michihiro Tsuchiya; hereinafter, "the Company") established a pharmaceutical sales and marketing company, MT Pharma America, Inc., and, at the same time, reorganized Group Companies in the United States. As of October 1, 2009, the names of three U.S. Group Companies, including MT Pharma America, were changed. Mitsubishi Tanabe Pharma hereby announces those new company names, and outlines the reorganization of Group Companies in the U.S.

Before the reorganization, the Company's U.S. subsidiaries included: Tanabe Research Laboratories U.S.A., Inc. (Head Office: California), pharmaceutical research, Tanabe U.S.A., Inc. (Head Office: California), sales and marketing of chemicals, and their holding company, Tanabe Holding America, Inc. (Head Office: New Jersey). In addition, the Company had Mitsubishi Pharma America, Inc. (Head Office: New Jersey), a pharmaceutical development company not affiliated with the holding company. In conjunction with the establishment of MT Pharma America in July 2009, the Company placed four Group Companies under the umbrella of the holding company: Tanabe Research Laboratories, Mitsubishi Pharma America, MT Pharma America and Tanabe U.S.A.

As of October 1, 2009, the Company changed the names of MT Pharma America, Tanabe Holding America and Mitsubishi Pharma America to Mitsubishi Tanabe Pharma America, Inc., Mitsubishi Tanabe Pharma Holdings America, Inc. and Mitsubishi Tanabe Pharma Development America, Inc., respectively.

In Medium-Term Management Plan 08-10, the Company sets forth as one of its key management issues the establishment of a foundation for pharmaceutical operations in the U.S. The Company is moving forward with development of MCI-196, a non-absorbed phosphate binder (indication: hyperphosphatemia), and MP-146, a uremic toxin adsorbent (indication: chronic kidney disease), in the U.S. and Europe, with phase 3 studies under way for each agent.

Upon obtaining approval, Mitsubishi Tanabe Pharma America will launch these products and start marketing and promotion activity in the U.S. market.


Reference

<Profile of U.S. Pharmaceutical Sales and Marketing Company>

- Company name: Mitsubishi Tanabe Pharma America, Inc.
- Location: New Jersey
- President: Takashi Nagao
- Paid-in capital: \$100 (Capital reserve: \$1,000,000)
- Shareholding company: Mitsubishi Tanabe Pharma Corporation (100%)
 - * Indirect ownership stake through a U.S. holding company, Mitsubishi Tanabe Pharma Holdings America
- Employees: 10 at time of establishment

<Overview of U.S. Group Companies>

(After establishment of MT Pharma America, reorganization and company name changes*)



For further information, contact:

Corporate Communications Department, Mitsubishi Tanabe Pharma Corporation

Phone: +81-6-6205-5211